This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Chaturvedi, N. Search for Related Content PubMed PubMed Citation Articles by Chaturvedi, N. Related Collections Epidemiology Related Article

(Circulation. 2009;119:2865-2867.)
© 2009 American Heart Association, Inc.

Editorial

Metabolic Memory in the Autonomic Neuropathy of Diabetes

Implications for Pathogenesis and Patient Care

Nishi Chaturvedi, MRCP

From the International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College NHS Healthcare Trust, London, United Kingdom.

Correspondence to N. Chaturvedi, Imperial College London, 59–61 N Wharf Rd, London, W2 1PG, United Kingdom. E-mail n.chaturvedi@imperial.ac.uk

Key Words: Editorials • diabetes mellitus • epidemiology

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Metabolic memory, the concept that historical glycemic control is a major determinant of diabetes complications, is of considerable interest not only to those involved in the care of people with diabetes mellitus but also to a wider audience, those wishing to understand the pathogenesis of hyperglycemia-related target organ damage. This phenomenon has been popularized clinically by the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC), which has repeatedly demonstrated the long-term impact of metabolic memory on nephropathy, retinopathy, cardiovascular disease, and peripheral neuropathy in type 1 diabetes mellitus.^1–3 An article in this issue of Circulation from the DCCT/EDIC Research Group demonstrates the same phenomenon for cardiac autonomic neuropathy (CAN).⁴ In the DCCT, intensive glycemic control over an average of 6.5 years achieved a marked reduction in hemoglobin A_1c, 1.7% lower than that achieved on conventional therapy, and a reduction in CAN incidence of 53%.⁵ At the termination of DCCT, all participants were encouraged to adopt intensive glycemic control such that 5 years after DCCT termination, there was no significant difference in hemoglobin A_1c between the originally randomized groups. At 13 to 14 years of follow up, CAN incidence subsequent to DCCT termination in those initially randomized to intensive control was reduced by a third compared with those randomized to conventional therapy, even though glycemic control had been identical in these groups for decade before the CAN assessment. Statistical adjustment for historical glycemic control, specifically that achieved during the DCCT itself, abolished the group difference in . . . [Full Text of this Article]

Related Article:

Effects of Prior Intensive Insulin Therapy on Cardiac Autonomic Nervous System Function in Type 1 Diabetes Mellitus: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC)

Rodica Pop-Busui, Phillip A. Low, Barbara H. Waberski, Catherine L. Martin, James W. Albers, Eva L. Feldman, Catherine Sommer, Patricia A. Cleary, John M. Lachin, William H. Herman for the DCCT/EDIC Research Group
Circulation 2009 119: 2886-2893. [Abstract] [Full Text]